今年6月7日,渤健(Biogen)基于β-淀粉样蛋白假说而开发的第一款用于治疗AD的单克隆抗体药物Aduhelm历经波折,终获得美国FDA批准上市,是近20年来AD领域首款新疗法...查看全文
$Trident(TDAC)$ DEF 14A Other definitive proxy statements Accession Number: 0001213900-20-038332 Act: 34 Size: 293 KB 网页链接
$Trident(TDAC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-20-037419 Act: 34 Size: 2 MB 网页链接
$Trident(TDAC)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001213900-20-035870 Act: 34 Size: 28 KB 网页链接
$Trident(TDAC)$ PRE 14A Other preliminary proxy statements Accession Number: 0001213900-20-034664 Act: 34 Size: 287 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001213900-20-033696 Size: 5 KB 网页链接
$Trident(TDAC)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001393825-20-000128 Size: 7 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001393825-20-000127 Size: 7 KB 网页链接
$Trident(TDAC)$ 8-K Current report, items 1.01, 5.03, 5.07, and 9.01 Accession Number: 0001213900-20-024717 Act: 34 Size: 53 KB 网页链接
$Trident(TDAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001076809-20-000137 Size: 6 KB 网页链接
$Trident(TDAC)$ DEF 14A Other definitive proxy statements Accession Number: 0001213900-20-022500 Act: 34 Size: 205 KB 网页链接